The company's lead candidate belrestotug is a TIGIT antagonist designed to activate immune cells, while its pipeline also includes inupadenant (A2AR antagonist), EOS-984 (ENT1 inhibitor), and EOS-215 (anti-TREM2 antibody). In 2025, iTeos announced a strategic shift, stating its intention to wind down operations and focus on maximizing shareholder value through its cash position and potential asset sales.
Cyborg Score Rationale
iTeos reported disappointing topline results from the GALAXIES Lung-201 Phase 2 study evaluating belrestotug + dostarlimab combination in first-line PD-L1 high NSCLC. The company is winding down operations and pursuing acquisition by Concentra after failing to advance its lead program in late-stage development, indicating fundamental strategic and clinical challenges.
Top Insights
Company agreed to acquisition by Concentra Biosciences at $10.047 per share plus contingent value rights
Lead candidate belrestotug + dostarlimab failed to meet clinical efficacy criteria in Phase 2 lung cancer trial
Strategic pivot to wind down operations and monetize assets rather than continue development
Company maintained strong cash position of $683.9 million as of September 2024
Named Competitors
Anti-TIGIT antibodies and checkpoint inhibitors — Partners and competitors in immuno-oncology space